Amplia Therapeutics appointed Tim Luscombe as CFO, succeeding Hamish George.

Prior to the executive appointment, Luscombe had worked with Amplia in a senior accounting role for the past two years.

Amplia focuses on developing focal adhesion kinase inhibitors for cancer and fibrosis treatments.